PHOENIX--(BUSINESS WIRE)--Synovics Pharmaceuticals, Inc. (OTCBB: SYVC), a specialty pharmaceutical company, today announced that it has entered into a binding letter of intent for exclusive, world-wide rights to the development and commercialization of the PharmPro Division of Fluid Air Inc.’s proprietary over-the-counter (OTC) version of omeprazole OTC. The U.S. market for the branded omeprazole OTC is greater than $600 million. There is presently no approved omeprazole OTC.
